What question did this study set out to answer?

The study aims to identify novel pre-treatment biomarkers in T-lymphocyte subpopulations associated with CAR T-cell therapy outcomes in diffuse large B-cell lymphoma patients.

January 17, 2026International Journal of Molecular SciencesOpen Access

Apheresis CD8+CCR7+CD45RA− T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome

View Full Paper

Ask AI

Bookmark

Authors

ITIván García de la TorreInstituto Ramón y Cajal de Investigación Sanitaria CGCarlota García-HozInstituto Ramón y Cajal de Investigación Sanitaria FMFernando Martin-MoroInstituto Ramón y Cajal de Investigación Sanitaria

Discussion

Member takes

Implication

This analysis identifies CD8+ central memory T-cells as predictors of CAR T-cell expansion and clinical success in lymphoma patients, indicating potential for better treatment strategies.

Key Points

The study aims to identify novel pre-treatment biomarkers in T-lymphocyte subpopulations associated with CAR T-cell therapy outcomes in diffuse large B-cell lymphoma patients.
Characterized T-lymphocyte subpopulations in apheresis samples from 23 patients
Performed immunophenotyping and multiparametric flow cytometry
Monitored CAR T-cell kinetics post-treatment
Median peak CAR T-cell count was 45.2 CAR T-cells/mL
Patients with >4.3% CD8+ central memory T-cells had significantly stronger CAR-T expansion (AUC: 0.80)
Higher CD8+ central memory T-cell frequencies predicted better progression-free survival (p = 0.04)

Cite This Study

Torre et al. (2026) studied this question.

synapsesocial.com/papers/696b25f3d2a12237a93494bf https://doi.org/10.3390/ijms27020866

View Full Paper

Ask AI

Bookmark

Implication

This analysis identifies CD8+ central memory T-cells as predictors of CAR T-cell expansion and clinical success in lymphoma patients, indicating potential for better treatment strategies.

Apheresis CD8+CCR7+CD45RA− T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome

Discussion

Member takes

Implication

Key Points

Cite This Study

Apheresis CD8+CCR7+CD45RA− T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider